<DOC>
	<DOCNO>NCT00911573</DOCNO>
	<brief_summary>The main purpose study compare safety efficacy tigecycline versus clindamycin ( include subject treat vancomycin ) pediatric subject ( age 8 17 year ) complicate skin skin structure infection ( cSSSI ) , include cause methicillin-resistant staphylococcus aureus ( MRSA ) .</brief_summary>
	<brief_title>Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus ( MRSA ) In Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Male female subject 8 17 year old . Children bone maturation le 8 year old enrolled caution due potential risk tooth discoloration . Have diagnosis serious infection require hospitalization administration IV antibiotic therapy . complicate skin skin structure infection ( cSSSI ) require significant surgical intervention involve deep soft tissue presence least one sign systemic infection Subject concomitant illness/condition , investigator 's judgment , substantially increase risk associate subject 's participation and/or completion study , could preclude evaluation subject 's response ( e.g. , life expectancy &lt; 30 day ) .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>pediatry</keyword>
	<keyword>child</keyword>
	<keyword>skin</keyword>
	<keyword>bacteria</keyword>
	<keyword>MRSA</keyword>
</DOC>